← boothcheck

Is AVAH overvalued?

boothcheck doesn't label AVAH overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, AVAH is priced for growth of +7.5%, and an operating margin near 2.6% versus the 10.5% it earns today. The price is supported by asset-based and relative-multiple and growth-DCF value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet. The more the price assumes beyond what Aveanna Healthcare Holdings Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from Aveanna Healthcare Holdings Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth+7.5%
For about
Margin needed2.6%
Margin today10.5%
Price vs asset value0.76x
Price vs earnings power5.21x
Price vs peer multiples0.64x
Price vs forward growth0.73x
Read the full AVAH report →
Get boothcheck's read on what AVAH's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.